J Gynecol Oncol | Volume 2, Issue 2 | Research Article | Open Access

Outcomes of Adjuvant Radiation Therapy and Chemotherapy in Uterine Carcinosarcoma

Yosra Yahyaoui, Chayma Bousrih, Wafa Sbika*, Amina Mokrani, Feriel Letaief, Khedija Meddeb, Mouna Ayadi, Nesrine Chraiet, Henda Raies and Amel Mezlini

Department of Medical Oncology, University of Tunis El Manar, Tunisia

*Correspondance to: Wafa Sbika 

Fulltext PDF

Abstract

To assess the impact on survival of adjuvant radiation therapy and chemotherapy in women with uterine Carcinosarcoma, a total of 44 patients were included in the cohort. Stages III-IV accounted for 20.5% and 43.2% respectively. Radiotherapy was delivered in 15 cases (34.1%) and chemotherapy was administered in 18.2% women with advanced stages. After a median follow up of 24.2 months, the 2-year progression free survival was 58.8% and the 2-year overall survival was 52.3%. In subgroups analysis, postoperative radiotherapy was associated with a better overall survival (HR, 4.02; 95% CI, 1.09-14.75; p=0.036). The combination of external beam pelvic radiation and vaginal brachytherapy improved significantly progression free survival ((HR, 0.28; 95% CI, 0.085-0.95; p=0.042). Systemic therapy did not show any survival benefit. The present study emphasizes the efficacy of radiation therapy in terms of progression free survival and overall survival. The role of chemotherapy warrants further investigations.

Keywords:

Carcinosarcoma; Uterine cancer; Radiation therapy; Chemotherapy

Citation:

Yahyaoui Y, Bousrih C, Sbika W, Mokrani A, Letaief F, Meddeb K, et al. Outcomes of Adjuvant Radiation Therapy and Chemotherapy in Uterine Carcinosarcoma. J Gynecol Oncol. 2019; 2(2): 1012.

Subscribe to Our Newsletter